Sangamo Therapeutics (SGMO) Lifted to “Strong-Buy” at BidaskClub

BidaskClub upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a strong-buy rating in a research note released on Saturday.

SGMO has been the subject of a number of other research reports. Piper Jaffray Companies upgraded Sangamo Therapeutics from a neutral rating to an overweight rating and set a $19.00 price target for the company in a report on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a hold rating to a buy rating and set a $14.00 price target for the company in a report on Wednesday, November 15th. Barclays began coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They set an overweight rating and a $20.00 target price for the company. Finally, Wedbush reiterated a neutral rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Sangamo Therapeutics has a consensus rating of Buy and an average price target of $18.83.

Sangamo Therapeutics (NASDAQ SGMO) opened at $23.30 on Friday. Sangamo Therapeutics has a fifty-two week low of $3.65 and a fifty-two week high of $23.75. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. Sangamo Therapeutics’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.27) EPS. sell-side analysts anticipate that Sangamo Therapeutics will post -0.73 EPS for the current fiscal year.

In other news, VP Curt A. Herberts III sold 16,630 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven J. Mento sold 11,520 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.59, for a total value of $237,196.80. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $102,950. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,953 shares of company stock valued at $1,544,843. Company insiders own 5.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in SGMO. Quantbot Technologies LP purchased a new position in shares of Sangamo Therapeutics during the 3rd quarter valued at approximately $118,000. Virtu KCG Holdings LLC acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at approximately $124,000. Fred Alger Management Inc. acquired a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at approximately $148,000. Amalgamated Bank acquired a new stake in shares of Sangamo Therapeutics during the 3rd quarter valued at approximately $158,000. Finally, Great West Life Assurance Co. Can raised its position in shares of Sangamo Therapeutics by 150.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 7,667 shares in the last quarter. Institutional investors own 64.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics (SGMO) Lifted to “Strong-Buy” at BidaskClub” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/18/sangamo-therapeutics-sgmo-lifted-to-strong-buy-at-bidaskclub.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply